Xywav (Calcium, magnesium, potassium, and sodium oxybates) for Narcolepsy

Overview
Xywav is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat cataplexy or excessive daytime sleepiness (EDS) in adults and children over 7 years of age with narcolepsy. Xywav is also referred to as calcium, magnesium, potassium, and sodium oxybates.

Xywav is a central nervous system (CNS) depressant, a drug that slows the functions of the CNS. Sodium oxybate (gamma hydroxybutyrate or GHB), one of the main ingredients of Xywav, is naturally produced by the body as an intermediate of the neurotransmitter GABA — which is involved in sleep regulation. Xywav is believed to work by mediating the actions of a GABAB protein receptor at specific neurons during sleep.

Xywav is a Schedule III controlled substance. Because GHB is abused recreationally by some people, Xywav is only available through a restricted program under the FDA’s Risk Evaluation and Mitigation Strategy called Xywav™ and Xyrem® REMS.

How do I take it?
Xywav is a clear oral solution taken twice a night, once before bed and again a few hours later.

Side effects
The FDA-approved label for Xywav lists common side effects including headache, nausea, dizziness, decreased appetite, disrupted sleep, diarrhea, excessive sweating, anxiety, and vomiting.

Less common but serious side effects for Xywav include impaired respiration, depression and suicidality, confusion, anxiety, and sleepwalking. Xywav should not be combined with any sedatives or alcohol. If you are pregnant or planning to become pregnant, talk to your doctor before taking Xywav.

For more details about this treatment, visit:

Xywav — Jazz Pharmaceuticals
https://www.xywav.com